Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 vaccines market in D-A-CH, consisting of Germany, Austria, and Switzerland, has seen significant growth since the rollout of vaccines began earlier this year.
Customer preferences: Customers in D-A-CH have shown a strong preference for mRNA vaccines such as Pfizer-BioNTech and Moderna. This preference is driven by the high efficacy rates of these vaccines and the perception of them being more advanced than traditional vaccines. However, there is also a growing demand for single-dose vaccines such as Johnson & Johnson, as they offer greater convenience and ease of use.
Trends in the market: In Germany, the COVID-19 vaccines market has seen a surge in demand as the country struggles to contain the spread of the Delta variant. The government has launched a campaign to encourage vaccination and has also introduced vaccine mandates for certain professions. In Austria, the market has seen a slower uptake of vaccines due to vaccine hesitancy among the population, particularly in rural areas. Switzerland has had a steady rollout of vaccines, with a focus on vaccinating vulnerable populations first.
Local special circumstances: In Germany, the vaccine rollout has been complicated by a federal system that gives individual states control over their own healthcare systems. This has led to disparities in vaccine availability and distribution across the country. In Austria, the government has faced criticism for its slow vaccine rollout, which has been attributed to a lack of coordination and communication. Switzerland has had a more successful rollout, but has faced challenges in vaccinating its large expat population.
Underlying macroeconomic factors: The COVID-19 vaccines market in D-A-CH is influenced by a number of macroeconomic factors, including government policies, healthcare infrastructure, and public trust in vaccines. The strong economies of Germany and Switzerland have allowed for significant investment in vaccine research and development, while Austria has struggled with a lack of resources. The high levels of public trust in vaccines in D-A-CH have also contributed to the success of the vaccine rollout, although vaccine hesitancy remains a concern in some areas.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
